Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [1] Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Armstrong, A. J.
    Iguchi, T.
    Azad, A. A.
    Szmulewitz, R. Z.
    Holzbeierlein, J.
    Villers, A.
    Alcaraz, A.
    Alekseev, B. Y.
    Shore, N. D.
    Petrylak, D. P.
    Rosbrook, B.
    Zohren, F.
    Yamada, S.
    Haas, G. P.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1300 - S1301
  • [2] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Armstrong, Andrew J.
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +
  • [3] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES
    von Bueren, Moritz
    Armstrong, Andrew J.
    Szmulewitz, Russell
    Petrylak, Daniel
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16S
  • [4] Phase 3 Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: the ARCHES Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 10 - 12
  • [5] Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial
    Stenzl, A.
    Krivoshik, A.
    Baron, B.
    Hirmand, M.
    Armstrong, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, Christopher J.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin M.
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, Thean Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Davis, Ian D.
    EUROPEAN UROLOGY, 2021, 80 (03) : 275 - 279
  • [7] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
    Iguchi, Taro
    Kimura, Go
    Fukasawa, Satoshi
    Suzuki, Hiroyoshi
    Uemura, Hiroji
    Nishimura, Kazuo
    Matsumoto, Hiroaki
    Yokomizo, Akira
    Armstrong, Andrew J.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Kunieda, Futoshi
    Stenzl, Arnulf
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (07) : 765 - 773
  • [8] Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study
    Stenzl, Arnulf
    Dunshee, Curtis
    De Giorgi, Ugo
    Alekseev, Boris
    Iguchi, Taro
    Szmulewitz, Russell Z.
    Flaig, Thomas W.
    Tombal, Bertrand
    Morlock, Robert
    Ivanescu, Cristina
    Ramaswamy, Krishnan
    Saad, Fred
    Armstrong, Andrew J.
    EUROPEAN UROLOGY, 2020, 78 (04) : 603 - 614
  • [9] Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, C. J.
    Martin, A. J.
    Stockler, M. R.
    Begbie, S.
    Chi, K. N.
    Chowdhury, S.
    Coskinas, X.
    Frydenberg, M.
    Hague, W. E.
    Horvath, L. G.
    Joshua, A. M.
    Lawrence, N. J.
    Marx, G. M.
    McCaffrey, J.
    McDermott, R.
    McJannett, M.
    North, S. A.
    Parnis, F.
    Parulekar, W.
    Pook, D. W.
    Reaume, M. N.
    Sandhu, S. K.
    Tan, A.
    Tan, T. H.
    Thomson, A.
    Tu, E.
    Vera-Badillo, F.
    Williams, S. G.
    Yip, S.
    Zhang, A. Y.
    Zielinski, R. R.
    Davis, I. D.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1519 - 1520
  • [10] TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)
    Chi, K. N.
    Chowdhury, S.
    Radziszewski, P.
    Lebret, T.
    Ozguroglu, M.
    Sternberg, C.
    Sims, R. B.
    Yu, M.
    Naini, V.
    Darif, M.
    Merseburger, A. S.
    ANNALS OF ONCOLOGY, 2016, 27
12345